Specialty and Branded Pharmaceuticals Sector Outlook — September 2026
This report compares how public markets price specialty and branded pharmaceutical business models—pipelines, hybrid portfolios and diversified platforms—on EV/Revenue, profitability and precedent transactions. Written for owners, boards and management teams weighing portfolio and capital choices.
For information only. Not an appraisal or a fairness opinion.
What moved since: Specialty and Branded Pharmaceuticals M&A update, 14–28 September 2026
Key figures
- Sector median EV/Revenue
- 2.7x
- CY2027E, 21 rated companies
- Premium tier multiple
- 5.1x
- highest rated EV/Revenue
- Discount tier multiple
- 1.0x
- lowest rated EV/Revenue
- Higher-margin cohort median
- 4.0x
- EBITDA margin above 29%
Read the report
1 / 23 · HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › SPECIALTY AND BRANDED PHARMACEUTICALS
Executive summary
Specialty and Branded Pharmaceuticals prices across three business models, with a sector median EV/Revenue (CY2027E) of 2.7x spanning a premium end of 5.1x and a discount end of 1.0x. Names above a 29% EBITDA margin threshold carry a median of 4.0x against 1.6x below it, and the cohort combining above-median growth and margin sits at 4.8x. Precedent transactions across the peer set reflect a wide range of pricing outcomes associated with asset maturity and portfolio fit.
Key findings
- Sector prices on forward revenue, with a median multiple of 2.7x.
- Premium and discount tiers diverge sharply: 5.1x versus 1.0x.
- Higher margins associate with higher pricing: 4.0x versus 1.6x below.
- Balanced growth and margin sit atop the operating screen at 4.8x.
What each page shows
The analyst’s walkthrough of the deck, page by page.
- 01
HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › SPECIALTY AND BRANDED PHARMACEUTICALS
Cover page introducing the September 2026 specialty and branded pharmaceuticals sector report.
We open with our September 2026 view of specialty and branded pharmaceuticals, built on EV/Revenue (CY2027E) as the primary valuation lens. This sets up the three-way split in business models that shapes everything that follows.
Everything on this page
HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › SPECIALTY AND BRANDED PHARMACEUTICALS Specialty Pharma: Valuation Splits Across Business Models This report shows where public pricing and precedent transactions distinguish franchise profiles across specialty pharma. September 2026 · Prepared by NeuraCap AI · Confidential Market data as of 2026-09-28 · primary valuation basis EV / Revenue (CY2027E) Specialty and Branded Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 1
- 02CONTENTS
What This Report Covers
This page lists the report's five sections plus the appendix.
We walk through five sections—the bottom line, the landscape, valuation and situations, precedent transactions, and strategic implications—plus a full appendix. We front-load the bottom line so a reader who stops after section one still gets the whole story, so we recommend starting there if time is short.
Everything on this page
CONTENTS What This Report Covers 01 The Bottom Line Specialty Pharma Supports Several Routes to Premium Pricing 02 The Landscape Business Model and Revenue Durability Frame the Valuation Case 03 Valuation & Situations Premium Pricing Spans Business Models and Demands a Durable Forecast 04 Precedent Transactions Precedent Transactions Price Specialty Assets on a Wide Range 05 Strategic Implications Higher Pricing Sits with Durable Revenue and Balanced Execution 06 Appendix Comparables Detail, Methodology, Sources and Assumptions Specialty and Branded Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 2
- 0301 · THE BOTTOM LINE
Specialty and Branded Pharmaceuticals Splits Three Ways: Pipelines, Hybrid Portfolios and Diversified Platforms
This page summarizes the report's central finding that specialty pharma splits into three business models with distinct valuation.
We find that specialty and branded pharmaceuticals splits three ways—pipelines, hybrid portfolios and diversified platforms—each priced differently on EV/Revenue (CY2027E). The sector median sits at 2.7x, but the premium end at 5.1x and the discount end at 1.0x show how differently the market treats revenue durability. Because practitioners price this industry on revenue rather than EBITDA, this is the lens that best supports comparison across models. So what: the multiple an owner defends depends on which of these three models the market believes the business fits.
Everything on this page
01 · THE BOTTOM LINE Specialty and Branded Pharmaceuticals Splits Three Ways: Pipelines, Hybrid Portfolios and Diversified Platforms The full story on one page · figures on EV / Revenue (CY2027E), market data as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Primary valuation basis: EV / Revenue on CY2027E consensus (21 of 25 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Practitioners price this industry on EV / Revenue rather than EV / EBITDA; validated coverage supports the industry standard (22 of 25 companies), so this report follows it. Qualitative characterisations are NeuraCap views. Specialty and Branded Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 3 1 Forward Revenue Is the Practical Valuation Lens 21 of 25 names have a forward revenue estimate, and the middle of the range is 2.7x. Revenue offers the broader comparison because only 13 of 25 names have meaningful forward EBITDA, often reflecting launch investment. 2 The Two Ends Carry Very Different Expectations The premium end sits at 5.1x, compared with 1.0x at the discount end. Because both use CY2027E revenue, the gap remains after forecast growth has already entered the denominator. 3 Revenue Quality Gives the Multiple Its Commercial Meaning Gross-to-net durability, formulary access and remaining exclusivity shape how owners can defend forecast revenue. Portfolio breadth and delivery complexity can also strengthen the case around durability. 4 Balanced Execution Sits Above Growth Alone On the 13 names with both growth and margin estimates, the 3 names clearing both bars sit at 4.8x. The 4 growth-only names sit at 1.6x, showing that forecast growth can carry very different pricing. 2.7x Sector median EV/Revenue CY2027E consensus · EV/Revenue is the lens because practitioners price this growth set on revenue and 2 of 25 names are… 5.1x Premium end EV/Revenue vs 1.0x at the discount end top quartile (n=6) against bottom quartile (n=4) on EV/Revenue — the spread the report explains 41 Transactions with disclosed terms 125 recorded in this tier · 3 told as case studies, the full list in the appendix
- 04SECTION 02
02
This divider introduces the section on business model and revenue durability.
We turn next to how business model and revenue durability drive the valuation case. Pipelines, hybrid portfolios and diversified platforms each expose owners to different launch, payer and exclusivity questions, so what follows sharpens where each model sits on that spectrum.
Everything on this page
SECTION 02 02 THE LANDSCAPE Business Model and Revenue Durability Frame the Valuation Case Pipelines, hybrid portfolios and diversified platforms expose owners to different launch, payer and exclusivity questions. 02 of 06 Specialty and Branded Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 4
- 0502 · MARKET MAP
Capital Sits Across Three Specialty Pharma Models: Pipelines, Hybrid Portfolios and Diversified Platforms
This page groups the approved company universe into three business-model segments and shows each group's median EV/Revenue.
We group the approved universe into pipelines, hybrid portfolios and diversified platforms and show each segment's median EV/Revenue (CY2027E). This map lets us see where capital concentrates before we dig into what drives the spread. So what: the segment a company sits in frames the multiple conversation before any company-specific detail enters.
Everything on this page
02 · MARKET MAP Capital Sits Across Three Specialty Pharma Models: Pipelines, Hybrid Portfolios and Diversified Platforms 25 approved companies grouped by business segment · median EV / Revenue (CY2027E) per group · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Segment grouping follows the platform's classification; group medians on rated names only. "Why it matters" lines are NeuraCap views. Specialty and Branded Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 5 PRE-COMMERCIAL BRANDED THERAPEUTIC PIPELINES 12 cos median 2.7x ASND AUPH TRVI ARDX PHAT TBPH ZVRA ACHV HRTX SLGL AKBA UNCY Pipeline-led businesses concentrate value in approval, launch execution and the protected life of a focused asset base. SPECIALTY BRAND AND AUTHORIZED-GENERIC HYBRID PORTFOLIOS 9 cos median 2.3x TAK ZTS ALKS INDV RGC ANIP PCRX EOLS DERM Hybrid portfolios combine branded economics with established commercial infrastructure and shared field-force potential. DIVERSIFIED BRANDED PHARMACEUTICAL PLATFORMS 3 cos median 2.7x NVS GSK SCLX Diversified platforms spread product and patent-cliff exposure across broader portfolios. ADJACENT: DIAGNOSTICS-ATTACHED SPECIALTY PHARMA PLATFORMS 1 cos 2.2x · 1 rated OPK The diagnostics-attached model links specialty products with a distinct channel and reimbursement profile.
- 0602 · LANDSCAPE
Franchise Models Differ, and so Do the Routes to Durable Revenue
This page explains what each business-model segment does and why its revenue durability differs.
We lay out what each segment does and why its route to durable revenue differs—from pipeline-stage assets to diversified platforms with broader portfolios. Full company-level detail sits in the appendix for any name a client wants to trace. So what: the durability story, not just the multiple, is what a buyer or owner needs to underwrite.
Everything on this page
02 · LANDSCAPE Franchise Models Differ, and so Do the Routes to Durable Revenue Segment view of the approved universe · EV / Revenue (CY2027E) medians on rated names · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. "What they do / why it matters" is a NeuraCap view. Full company-level detail in the appendix and companion tables. Specialty and Branded Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 6 Segment n Share of universe Median EV/Revenue Names to know What they do — and why it matters Pre-commercial branded therapeutic pipelines 12 48% 2.7x Ascendis Pharma A/S (ASND) · Aurinia Pharmaceuticals Inc. (AUPH) · +10 more Milestones concentrate the value. Approval, payer access and launch uptake can change the revenue base quickly, while sole-asset concentration keeps the exclusivity clock central. Specialty brand and authorized-generic hybrid portfolios 9 36% 2.3x Takeda Pharmaceutical Company Limited (TAK) · Zoetis Inc. (ZTS) · +7 more Commercial infrastructure carries weight. Shared prescriber coverage, disciplined gross-to-net management and portfolio mix determine how efficiently these businesses support multiple products. Diversified branded pharmaceutical platforms 3 12% 2.7x Novartis AG (NVS) · GSK plc (GSK) · +1 more Breadth spreads portfolio risk. Broader product sets can absorb individual patent cliffs more effectively, making capital allocation and pipeline replenishment central to the value case. Adjacent: diagnostics-attached specialty pharma platforms 1 4% 2.2x n=1 OPKO Health, Inc. (OPK) Channel economics shape performance. Diagnostics attachment adds a distinct reimbursement and customer pathway, so channel fit matters alongside pharmaceutical demand.
- 07SECTION 03
03
This divider introduces the section on public market valuation.
We move now to public market valuation, where premium pricing spans every business model in the peer set. Because the forward revenue lens already credits expected growth, the bar for defending a premium is higher than it first appears.
Everything on this page
SECTION 03 03 VALUATION & SITUATIONS Premium Pricing Spans Business Models and Demands a Durable Forecast The forward revenue lens already credits expected growth, raising the bar for defending a premium. 03 of 06 Specialty and Branded Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 7
- 0803 · PUBLIC MARKET VALUATION
Premium Pricing Persists After Forecast Growth Enters the Revenue Base
This page ranks all rated companies by EV/Revenue (CY2027E) and marks the sector median.
We rank all 21 rated companies by EV/Revenue (CY2027E), anchored to a sector median of 2.7x. We use this lens because practitioners price this growth set on revenue, and 2 of 25 names are loss-making on forward EBITDA. So what: this ranking is the starting point for every valuation conversation that follows, from premium tier to discount tier.
Everything on this page
03 · PUBLIC MARKET VALUATION Premium Pricing Persists After Forecast Growth Enters the Revenue Base EV / Revenue (CY2027E) · all 21 rated companies, sorted descending · sector median 2.7x · EV/Revenue is the lens because practitioners price this growth set on revenue and 2 of 25 names are loss-making on forward EBITDA · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Primary valuation basis: EV / Revenue on CY2027E consensus (21 of 25 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Practitioners price this industry on EV / Revenue rather than EV / EBITDA; validated coverage supports the industry standard (22 of 25 companies), so this report follows it. Tier zones are NeuraCap groupings cut at the rated set's quartiles; every multiple quoted on this page is a median on the same EV / Revenue (CY2027E) basis. Panel commentary is a NeuraCap view. Specialty and Branded Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 8 PREMIUM · median 5.1x CORE · median 2.2x DISCOUNT · median 1.0x Sector median 2.7x WHAT SEPARATES THE TWO ENDS Premium pricing spans models. The premium end carries a 5.1x CY2027E EV / Revenue multiple, with pipeline-led, hybrid and diversified names represented. Discount pricing marks uncertainty. The discount end sits at 1.0x, pointing to a lower market view of forecast revenue quality, durability or execution. Forward pricing tests durability. A CY2027E multiple already credits forecast growth. A premium that remains on that basis signals that investors are also underwriting durability beyond the near-term ramp.
- 0903 · VALUATION DRIVERS
Profitability Separates the Two Ends: Names Above the 29% Margin Line Carry 4.0x Against 1.6x Below It
This page compares median EV/Revenue for higher-margin and lower-margin cohorts split at the 29% covered median.
We split the rated set at its covered median EBITDA margin of 29% and find the higher-margin cohort priced at 4.0x against 1.6x for the lower-margin cohort. This is an association we observe in the data, not a causal claim. So what: margin discipline appears to matter as much as growth when the market sets a premium.
Everything on this page
03 · VALUATION DRIVERS Profitability Separates the Two Ends: Names Above the 29% Margin Line Carry 4.0x Against 1.6x Below It Median EV / Revenue (CY2027E) by revenue-growth cohort and by EBITDA-margin cohort (each split at its covered median) · rated names with estimates · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Cohort medians on rated names with the required estimates (faster n=10; slower n=10; higher-margin n=7; lower-margin n=6). Driver readings are NeuraCap views on the supplied data — association, not causation. Specialty and Branded Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 9 EV/Revenue, median per cohort · growth split at 6% · EBITDA-margin split at 29% The Growth Split Runs Against a Simple Premium Story Names above the 6% growth split sit at 2.1x, while names below it sit at 2.8x. The observed pricing therefore does not support growth alone as a sufficient explanation. Profitability Changes the Reading of Growth The balanced group sits above the growth-only group, associating higher pricing with a combination of revenue growth and margin delivery. Revenue Durability Remains Central Exclusivity runway, net realised price, formulary position and refill persistence frame whether forecast revenue can hold after launch investment normalizes.
- 1003 · SITUATION MAP
Premium Pricing Includes Both Growth Leaders and Slower-Growth Franchises
This page maps rated companies on EV/Revenue versus revenue growth, both cut at their covered medians.
We cut the rated set on EV/Revenue against the sector median of 2.7x and on revenue growth against the covered median of 6%, producing four situations rather than one story. Premium pricing shows up among both growth leaders and slower-growth franchises. So what: growth alone doesn't explain who commands the premium.
Everything on this page
03 · SITUATION MAP Premium Pricing Includes Both Growth Leaders and Slower-Growth Franchises Cut on EV / Revenue vs the sector median (2.7x) (rows) and revenue growth vs the covered median (6%) (columns) · 1 rated names without the second measure are not mapped · observations, not recommendations Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Situation boundaries are the cohort's own medians (Directional, NeuraCap view). This page characterises situations; it does not recommend buying or selling any security. Specialty and Branded Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 10 Premium with Growth Above-median multiple · above-median revenue growth 5 names Ascendis Pharma A/S (ASND) · Alkermes plc (ALKS) · Indivior Pharmaceuticals Inc (INDV) · +2 more These names combine above-line growth with above-line pricing. The value case rests on sustaining growth while protecting net realised price and margin quality. Premium with Slower Growth Above-median multiple · below-median revenue growth 6 names Novartis AG (NVS) · GSK plc (GSK) · Takeda Pharmaceutical Company Limited (TAK) · +3 more These names carry above-line pricing despite slower growth. Portfolio breadth, profitability or perceived revenue durability may be associated with that position. Growth Awaiting Recognition Below-median multiple · above-median revenue growth 5 names ANI Pharmaceuticals, Inc. (ANIP) · Ardelyx, Inc. (ARDX) · Evolus, Inc. (EOLS) · +2 more These names post above-line growth while remaining below the pricing line. The operating question is whether retention, payer access and cost structure can turn growth into a more durable value case. Execution and Pricing Gap Below-median multiple · below-median revenue growth 4 names OPKO Health, Inc. (OPK) · Pacira BioSciences, Inc. (PCRX) · Heron Therapeutics, Inc. (HRTX) · +1 more These names sit below both lines. Improving revenue mix, cost structure or portfolio focus would change the evidence available to investors and strategic buyers.
- 1103 · GROWTH VS PROFITABILITY
Balanced Growth and Margin Sit at the Top of the Range in the Operating Screen
This page plots companies on revenue growth versus EBITDA margin and shows median EV/Revenue per quadrant.
We plot the 13 companies with both growth and margin estimates against covered medians of 12% growth and 29% margin, and the quadrant that balances both sits at the top of the range at 4.8x. So what: balanced execution—not growth or margin alone—appears to be what the market rewards most.
Everything on this page
03 · GROWTH VS PROFITABILITY Balanced Growth and Margin Sit at the Top of the Range in the Operating Screen Revenue growth (CY2026E, x-axis) vs EBITDA margin (CY2027E, y-axis) · 13 companies with both estimates · cuts at the covered medians (12% growth, 29% margin) · median EV/Revenue per quadrant · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Quadrant cuts are the covered set's medians. Quadrant medians on names with a meaningful EV/Revenue (balanced n=3; margin-only n=4; growth-only n=4; neither n=2). Specialty and Branded Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 11 0% 20% 40% 60% 80% 20% 40% 60% MARGIN ONLY median 3.7x BALANCED median 4.8x NEITHER median 2.3x GROWTH ONLY median 1.6x ZTS TAK GSK PCRX NVS INDV EOLS AUPH ARDX ALKS ANIP PHAT ASND x: revenue growth (CY2026E) · y: EBITDA margin (CY2027E) HOW TO READ THIS Among the 13 names with both estimates, 3 clear the 12% growth and 29% margin bars and sit at 4.8x. The 4 margin-only names sit at 3.7x, while the 4 growth-only names sit at 1.6x. The 2 names clearing neither bar sit at 2.3x. The pattern associates balanced execution with higher pricing in this sample. The growth-only median rests on 4 names and is lifted by ALKS at 4.0x. Rule of 40 (revenue growth + EBITDA margin ≥ 40%): 6 of 13 names clear it (ASND, NVS, AUPH, INDV, ANIP, PHAT).
- 1203 · THE AGENDA
The Higher Valuations Sit with Operating Models Built on Durable Revenue
This page frames the questions an owner or acquirer should resolve given where higher valuations sit.
We frame the open questions for owners and acquirers: which operating levers—revenue durability, growth, margin—help explain where the higher valuations sit. These are observations grounded in the cohort data we've shown, not recommendations to buy or sell any security. So what: the questions here set the agenda for the strategic implications later in the deck.
Everything on this page
03 · THE AGENDA The Higher Valuations Sit with Operating Models Built on Durable Revenue NeuraCap view · framed as the questions an owner or acquirer should resolve · observations, not recommendations Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All content on this page is Directional — NeuraCap advisory judgment grounded in the cohort data shown earlier. It does not constitute investment advice. Specialty and Branded Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 12 Protect Revenue Quality Focus the operating plan on net realised price, refill persistence, formulary access and gross-to-net discipline across priority brands. What changes the answer: The answer changes when script growth requires materially greater rebates or patient assistance. Broaden the Franchise Base Test label expansion, adjacent indications and portfolio additions that can use existing prescriber access and commercial infrastructure. What changes the answer: The answer changes when a new asset requires a separate field force, channel or reimbursement model. Match Costs to Maturity Align launch investment and field-force reach with patient starts, refill behavior and the pace of covered-lives access. What changes the answer: The answer changes when commercial productivity remains below the level needed to support the cost base. Choose Build Versus Buy Compare internal pipeline investment with acquiring brands or companies that add revenue, exclusivity runway or commercial fit. What changes the answer: The answer changes when external assets offer a clearer route to portfolio breadth than internal development.
- 13SECTION 04
04
This divider introduces the section on precedent transactions.
We turn now to precedent transactions, which price specialty assets across a wide range. Asset maturity, portfolio fit and commercial durability remain central to interpreting what buyers agreed to pay.
Everything on this page
SECTION 04 04 PRECEDENT TRANSACTIONS Precedent Transactions Price Specialty Assets on a Wide Range Asset maturity, portfolio fit and commercial durability remain central to interpreting what buyers agreed to pay. 04 of 06 Specialty and Branded Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 13
- 1404 · DEAL CASE STUDIES
Precedent Transactions Span Mature Portfolios and Focused Specialty Assets
This page presents three precedent transactions as case studies, drawn from a set of 41 deals with disclosed terms.
We walk through 3 of 41 transactions with disclosed terms as case studies, with multiples on LTM financials at announcement. These deal multiples aren't directly comparable to the CY2027E public basis, so we don't claim a spread between the two. So what: the case studies illustrate why buyers paid what they did, and the complete list sits in the appendix for further reference.
Everything on this page
04 · DEAL CASE STUDIES Precedent Transactions Span Mature Portfolios and Focused Specialty Assets 3 of 41 transactions with disclosed terms, told as case studies · multiples on LTM financials at announcement where disclosed · the complete list is in the appendix · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 151 precedent record(s) carry data-quality flags (deal value unit unresolved; divestiture roles reassigned; duplicate precedent id); figures are shown as recorded in the filing. 84 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. "Why the deal happened" is a NeuraCap read of the recorded evidence. Specialty and Branded Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 14 Nov-2021 $17.9B Merck & Co., Inc. acquires Organon & Co. EV / LTM revenue 2.8x EV / LTM EBITDA n/a WHY THE DEAL HAPPENED The transaction broadens the evidence on what buyers agreed to pay for whole companies in the sector. HOW THE TARGET WAS VALUED Its valuation is most useful as part of the transaction range rather than as a stand-alone anchor. Apr-2026 $11.9B Sun Pharmaceutical Holdings USA, Inc. Sun Pharmaceutical Holdings USA, Inc. agreed to acquire Organon & Co. at portfolio scale. EV / LTM revenue 1.9x EV / LTM EBITDA 6.5x WHY THE DEAL HAPPENED The transaction suggests a strategy centered on adding a broad commercial franchise to an established pharmaceutical platform. Organon & Co.'s portfolio profile offers scale beyond a single focused asset. HOW THE TARGET WAS VALUED The announced value was $11.9B, equal to 1.9x revenue and 6.5x EBITDA. The revenue multiple sits below the middle of the public peer range. Aug-2025 $299M MannKind Corporation MannKind Corporation agreed to acquire scPharmaceuticals Inc. as a focused specialty addition. EV / LTM revenue 2.1x EV / LTM EBITDA n/a WHY THE DEAL HAPPENED The transaction suggests that MannKind Corporation saw value in adding a commercial specialty franchise to its existing platform. The fit points to potential relevance across commercial infrastructure and prescriber reach. HOW THE TARGET WAS VALUED The announced value was $299M at 2.1x revenue. That pricing sits below the middle of the public peer range.
- 15SECTION 05
05
This divider introduces the section on strategic implications.
We close the analysis with strategic implications, where higher pricing sits with durable revenue and balanced execution. The operating agenda ahead centers on revenue quality, exclusivity, cost structure and disciplined portfolio choices.
Everything on this page
SECTION 05 05 STRATEGIC IMPLICATIONS Higher Pricing Sits with Durable Revenue and Balanced Execution The operating agenda centers on revenue quality, exclusivity, cost structure and disciplined portfolio choices. 05 of 06 Specialty and Branded Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 15
- 1605 · STRATEGIC IMPLICATIONS
The Value Agenda Centers on Revenue Durability and Balanced Execution
This page sets out the value agenda centered on revenue durability and balanced execution for the next twelve months.
We put forward the questions this data raises for owners, management teams and boards over the next twelve months: protecting revenue quality, broadening the franchise base, matching costs to maturity, and choosing build versus buy. These are directional views grounded in the analysis, not recommendations. So what: this agenda gives a starting point for the operating and portfolio conversations the multiple spread demands.
Everything on this page
05 · STRATEGIC IMPLICATIONS The Value Agenda Centers on Revenue Durability and Balanced Execution NeuraCap view · the questions this data puts on the table for the next twelve months Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. This page is Directional — NeuraCap views drawn from the analysis in this report. Observations, not recommendations. Specialty and Branded Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 16 FOR OWNERS Build Durability into the Operating Plan Prioritize revenue mix, payer access, refill persistence and exclusivity runway alongside growth. The peer set associates balanced growth and margin delivery with higher pricing. FOR MANAGEMENT TEAMS Concentrate Resources Where Economics Hold Direct field-force, hub services and patient assistance toward brands where net realised price and persistence support durable contribution. FOR BOARDS Test Portfolio Choices Against the Clock Evaluate capital allocation, label expansion and build-versus-buy choices against patent-cliff timing and the ability to reuse commercial infrastructure.
- 17SECTION 06
06
This divider introduces the appendix covering the full universe, methodology and sources.
We close with the full comparable universe, the methodology behind every figure, and where each underlying disclosure lives. This is the reference section for any number a client wants to trace back to its source.
Everything on this page
SECTION 06 06 APPENDIX The Full Universe, Methodology and Sources Comparables detail behind every figure in the body, the valuation basis, and where each underlying disclosure lives. 06 of 06 Specialty and Branded Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 17
- 1806 · PUBLIC COMPARABLES (1 OF 2)
Public Comparables on EV / Revenue (CY2027E), Grouped by Valuation Tier
This page lists public comparables on EV/Revenue (CY2027E), grouped by valuation tier, for the first half of the rated set.
We list all 21 rated companies on EV/Revenue (CY2027E), shaded above and below the sector median of 2.7x, with tickers linking to the underlying source. 4 companies in the universe are not rated because they lack an eligible multiple. So what: this is the full comparable set behind every multiple quoted earlier in the deck.
Everything on this page
06 · PUBLIC COMPARABLES (1 OF 2) Public Comparables on EV / Revenue (CY2027E), Grouped by Valuation Tier Teal shading marks a EV/Revenue above the sector median (2.7x); amber marks below · 21 rated companies; 4 not rated (no eligible EV/Revenue) · tickers link to the underlying source · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All 21 rated rows are in this appendix and in the companion workbook, which carries the complete field set. Names without an eligible multiple are listed in the companion workbook. Specialty and Branded Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 18 Company Ticker Segment EV EV/Revenue (CY2027E) Rev growth EBITDA margin Rule of 40 PREMIUM — ≥4.0x · median 5.1x · 6 companies Sol-Gel Technologies Ltd. SLGL Pre-commercial branded therapeutic pipelines $142M 94.3x -96% n/a n/a Ascendis Pharma A/S ASND Pre-commercial branded therapeutic pipelines $14.6B 6.4x 84% 36% 82 Novartis AG NVS Diversified branded pharmaceutical platforms $321B 5.3x 4% 41% 48 Theravance Biopharma Inc TBPH Pre-commercial branded therapeutic pipelines $523M 5.0x -21% n/a n/a Aurinia Pharmaceuticals Inc. AUPH Pre-commercial branded therapeutic pipelines $1.9B 4.8x 17% 65% 82 Alkermes plc ALKS Specialty brand and authorized-generic hybrid portfolios $7.8B 4.0x 24% 11% 17 CORE — 1.3x–4.0x · median 2.2x · 11 companies Zoetis Inc. ZTS Specialty brand and authorized-generic hybrid portfolios $37.3B 4.0x -2% 41% 43 Indivior Pharmaceuticals Inc INDV Specialty brand and authorized-generic hybrid portfolios $4.8B 3.5x 8% 49% 55 Takeda Pharmaceutical Company Limited TAK Specialty brand and authorized-generic hybrid portfolios $87.3B 3.0x -1% 28% 27 GSK plc GSK Diversified branded pharmaceutical platforms $126B 2.7x 3% 34% 38 Zevra Therapeutics, Inc. ZVRA Pre-commercial branded therapeutic pipelines $469M 2.7x 43% n/a n/a OPKO Health, Inc. OPK Adjacent: diagnostics-attached specialty pharma… $1.3B 2.2x -6% n/a n/a ANI Pharmaceuticals, Inc. ANIP Specialty brand and authorized-generic hybrid portfolios $2.0B 1.6x 25% 26% 38 Evolus, Inc. EOLS Specialty brand and authorized-generic hybrid portfolios $639M 1.6x 12% 10% 28 Pacira BioSciences, Inc. PCRX Specialty brand and authorized-generic hybrid portfolios $1.2B 1.5x 4% 26% 30
- 1906 · PUBLIC COMPARABLES (2 OF 2)
Public Comparables on EV / Revenue (CY2027E), Grouped by Valuation Tier
This page continues the public comparables list on EV/Revenue (CY2027E), grouped by valuation tier.
We continue the full comparable list here, still shaded against the sector median of 2.7x, so a client can trace any individual company's position. The companion workbook carries the complete field set for every name shown. So what: nothing in the ranking on the earlier pages rests on a company we haven't shown here.
Everything on this page
06 · PUBLIC COMPARABLES (2 OF 2) Public Comparables on EV / Revenue (CY2027E), Grouped by Valuation Tier Teal shading marks a EV/Revenue above the sector median (2.7x); amber marks below · 21 rated companies; 4 not rated (no eligible EV/Revenue) · tickers link to the underlying source · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All 21 rated rows are in this appendix and in the companion workbook, which carries the complete field set. Names without an eligible multiple are listed in the companion workbook. Specialty and Branded Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 19 Company Ticker Segment EV EV/Revenue (CY2027E) Rev growth EBITDA margin Rule of 40 CORE — CONTINUED — 1.3x–4.0x · median 2.2x · 11 companies Journey Medical Corporation DERM Specialty brand and authorized-generic hybrid portfolios $175M 1.3x 32% n/a n/a Ardelyx, Inc. ARDX Pre-commercial branded therapeutic pipelines $812M 1.3x 20% 17% 45 DISCOUNT — <1.3x · median 1.0x · 4 companies Phathom Pharmaceuticals, Inc. PHAT Pre-commercial branded therapeutic pipelines $569M 1.2x 81% 29% 86 Heron Therapeutics, Inc. HRTX Pre-commercial branded therapeutic pipelines $153M 1.1x -4% n/a n/a Akebia Therapeutics, Inc. AKBA Pre-commercial branded therapeutic pipelines $128M 1.0x -16% n/a n/a Scilex Holding Company SCLX Diversified branded pharmaceutical platforms $116M 0.6x n/a n/a n/a
- 2006 · PRECEDENT TRANSACTIONS (1 OF 2)
All Precedent Transactions with Disclosed Terms, Newest First
This page lists precedent transactions with disclosed terms, newest first, for the first half of the set shown.
We list 18 of 41 transactions with disclosed terms here, newest first, with multiples on LTM financials at announcement and deal values linking to the underlying filing. The remaining transactions sit in the companion workbook. So what: this is the primary evidence behind the deal case studies discussed earlier.
Everything on this page
06 · PRECEDENT TRANSACTIONS (1 OF 2) All Precedent Transactions with Disclosed Terms, Newest First 41 transactions with disclosed terms in this tier (125 recorded) · multiples on LTM financials at announcement where disclosed · deal values link to the underlying filing · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 151 precedent record(s) carry data-quality flags (deal value unit unresolved; divestiture roles reassigned; duplicate precedent id); figures are shown as recorded in the filing. 84 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. 18 of 41 transactions shown; the rest are in the companion workbook. Specialty and Branded Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 20 Date Transaction EV EV/LTM Rev EV/LTM EBITDA Why it matters Apr-2026 Sun Pharmaceutical Holdings USA, Inc. → Organon & Co. $11.9B 1.9x 6.5x Sun Pharmaceutical Holdings USA, Inc. and Organon & Co. show how a large commercial portfolio can enter the transaction record at substantial scale. Apr-2026 Garda Therapeutics, Inc. → Assertio Holdings, Inc. $166M 1.6x n/a Value shown as recorded in the filing; deal value unit unresolved. Mar-2026 Aurinia Pharma U.S., Inc. → Kezar Life Sciences, Inc. $26M 7.8x n/a Aurinia Pharma U.S., Inc. and Kezar Life Sciences, Inc. show that smaller transaction values can still carry high revenue pricing. Mar-2026 Merck Sharp & Dohme LLC → Terns Pharmaceuticals, Inc. $4.4B n/a n/a Value shown as recorded in the filing; deal value unit unresolved. Aug-2025 MannKind Corporation → scPharmaceuticals Inc. $299M 2.1x n/a MannKind Corporation and scPharmaceuticals Inc. illustrate how a specialty platform can add a complementary commercial franchise. Mar-2025 Jazz Pharmaceuticals plc → Chimerix, Inc. $736M n/a n/a Value shown as recorded in the filing; deal value unit unresolved. Mar-2025 Paratek Phamaceuticals Inc. → OptiNose Inc. n/a 2.1x n/a Value shown as recorded in the filing; deal value unit unresolved. Apr-2024 Ono Pharmaceutical Co., Ltd. → Deciphera Pharmaceuticals, Inc. n/a 6.9x n/a Dec-2023 Future Pak, LLC → Vanda Pharmaceuticals Inc. $112M 0.6x n/a Value shown as recorded in the filing; deal value unit unresolved.
- 2106 · PRECEDENT TRANSACTIONS (2 OF 2)
All Precedent Transactions with Disclosed Terms, Newest First
This page continues the list of precedent transactions with disclosed terms, newest first.
We continue the transaction list here, on the same LTM-at-announcement basis, so a client can review the full disclosed set in one place. The companion workbook holds the balance of the recorded transactions. So what: this closes out the transaction evidence supporting the deal discussion in this report.
Everything on this page
06 · PRECEDENT TRANSACTIONS (2 OF 2) All Precedent Transactions with Disclosed Terms, Newest First 41 transactions with disclosed terms in this tier (125 recorded) · multiples on LTM financials at announcement where disclosed · deal values link to the underlying filing · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 151 precedent record(s) carry data-quality flags (deal value unit unresolved; divestiture roles reassigned; duplicate precedent id); figures are shown as recorded in the filing. 84 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. 18 of 41 transactions shown; the rest are in the companion workbook. Specialty and Branded Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 21 Date Transaction EV EV/LTM Rev EV/LTM EBITDA Why it matters Apr-2023 Assertio Holdings, Inc. → Spectrum Pharmaceuticals, Inc. $3.3B n/a n/a Value shown as recorded in the filing; deal value unit unresolved. Jan-2023 Chiesi Farmaceutici S.p.A. → Amryt Pharma plc n/a 2.1x n/a Nov-2022 Indivior PLC → Opiant Pharmaceuticals, Inc. n/a n/a 8.8x Value shown as recorded in the filing; deal value unit unresolved. Oct-2022 Amgen Inc. → ChemoCentryx, Inc. n/a 4.1x n/a Sep-2022 Pfizer Inc. → Biohaven Ltd. n/a 4.6x n/a Aug-2022 Innoviva Specialty Therapeutics, Inc. → La Jolla Pharmaceutical Company n/a 1.9x n/a Value shown as recorded in the filing; deal value unit unresolved. Mar-2022 Axsome Therapeutics → Sunosi (division of Jazz Pharmaceuticals plc) n/a 0.9x n/a Value shown as recorded in the filing; deal value unit unresolved. Feb-2022 Collegium Pharmaceutical, Inc. → BioDelivery Sciences International, Inc. n/a 2.7x 11.9x Value shown as recorded in the filing; deal value unit unresolved. Jan-2022 Amneal Pharmaceuticals, Inc. → Saol Therapeutics n/a 3.3x n/a Value shown as recorded in the filing; deal value unit unresolved.
- 2206 · METHODOLOGY
Sources, Assumptions and Data Quality
This page explains the report's sources, assumptions and data-quality treatment.
We show how this report was built: what was included, what was excluded, and where every underlying disclosure lives. Every figure in this report links back to the record it was taken from. So what: a client can verify any number in this deck against its original source.
Everything on this page
06 · METHODOLOGY Sources, Assumptions and Data Quality How this report was built, what was excluded, and where every underlying disclosure lives · as of 2026-09-28 Every figure in this report links to the record it was taken from. Where a figure has no link, the appendix names its source and the basis on which it was read. Specialty and Branded Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice 22 VALUATION BASIS Primary valuation basis: EV / Revenue on CY2027E consensus (21 of 25 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Practitioners price this industry on EV / Revenue rather than EV / EBITDA; validated coverage supports the industry standard (22 of 25 companies), so this report follows it. EV / Revenue on CY2027E is the lead convention: it is the sector-appropriate prior for Specialty and Branded Pharmaceuticals and it clears the coverage gate with 21 of 25 companies (84%). P / E is carried as a cross-check. A revenue lens is used rather than a profit multiple because the set is not consistently profitable on a forward basis (13 of 25 names with a meaningful EBITDA). DATA QUALITY & EXCLUSIONS 58 records were excluded or quarantined by the platform's validation gates (unit errors, implausible ratios, ineligible securities and classification failures); the full ledger ships in the companion tables and never feeds a statistic in this report. DEFINITIVE VS DIRECTIONAL Definitive content is disclosed or consensus data passed through stated arithmetic. Directional content — tier boundaries, situation cuts, "why it matters" commentary, the agenda pages — is NeuraCap analyst judgment and is labeled as such where it appears. WHAT THIS REPORT IS NOT This report characterises a sector. It does not recommend buying, selling or holding any security, and no statement in it should be read as investment advice or a price target. WHERE THE DATA LIVES 828 registered source documents stand behind the figures in this report. Metric hyperlinks throughout the deck open the specific filing or data record; by publisher: sec.gov (827) · home.treasury.gov (1). The companion workbook beside this deck carries the complete source index.
- 23
Premium Pricing Appears Across Several Franchise Profiles in the Peer Set.
This closing page restates that premium pricing appears across several franchise profiles in the peer set.
We close on the finding that premium pricing appears across several franchise profiles in this peer set, not just one business model. The companion tables carry the full universe, the exclusion ledger and the complete source index for any figure a client wants to trace.
Everything on this page
Premium Pricing Appears Across Several Franchise Profiles in the Peer Set. NeuraCap AI — Specialty and Branded Pharmaceuticals Coverage September 2026 · Prepared by NeuraCap AI · Confidential Specialty and Branded Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 23
Sources and methodology
This report covers Specialty and Branded Pharmaceuticals (Health Care › Pharmaceuticals, Biotechnology and Life Sciences › Specialty and Branded Pharmaceuticals) with market data and consensus estimates as of September 28, 2026. The company universe is the 25 listed companies whose core business is Specialty and Branded Pharmaceuticals according to NeuraCap's industry classification of each company's reported business segments (a company is included only when this industry is central to what it does, not merely adjacent to it). Companies in the set: Achieve Life Sciences, Inc. (ACHV), Akebia Therapeutics, Inc. (AKBA), Alkermes plc (ALKS), ANI Pharmaceuticals, Inc. (ANIP), Ardelyx, Inc. (ARDX), Ascendis Pharma A/S (ASND), Aurinia Pharmaceuticals Inc. (AUPH), Journey Medical Corporation (DERM), Evolus, Inc. (EOLS), GSK plc (GSK), Heron Therapeutics, Inc. (HRTX), Indivior Pharmaceuticals Inc (INDV), Novartis AG (NVS), OPKO Health, Inc. (OPK), Pacira BioSciences, Inc. (PCRX), Phathom Pharmaceuticals, Inc. (PHAT), Regencell Bioscience Holdings Limited (RGC), Scilex Holding Company (SCLX), Sol-Gel Technologies Ltd. (SLGL), Takeda Pharmaceutical Company Limited (TAK), Theravance Biopharma Inc (TBPH), Trevi Therapeutics, Inc. (TRVI), Unicycive Therapeutics, Inc. (UNCY), Zoetis Inc. (ZTS), Zevra Therapeutics, Inc. (ZVRA). The market map groups them by business vertical — Pre-commercial branded therapeutic pipelines: 12 companies (ASND, AUPH, TRVI, ARDX, PHAT, TBPH, ZVRA, ACHV, HRTX, SLGL, AKBA, UNCY); Specialty brand and authorized-generic hybrid portfolios: 9 companies (TAK, ZTS, ALKS, INDV, RGC, ANIP, PCRX, EOLS, DERM); Diversified branded pharmaceutical platforms: 3 companies (NVS, GSK, SCLX); Adjacent: diagnostics-attached specialty pharma platforms: 1 company (OPK). 21 of the 25 companies carry a valid multiple on the primary valuation basis and form the rated set behind every cohort statistic; the others are shown but do not enter the statistics.
Scope and company universe
This report covers Specialty and Branded Pharmaceuticals (Health Care › Pharmaceuticals, Biotechnology and Life Sciences › Specialty and Branded Pharmaceuticals) with market data and consensus estimates as of September 28, 2026. The company universe is the 25 listed companies whose core business is Specialty and Branded Pharmaceuticals according to NeuraCap's industry classification of each company's reported business segments (a company is included only when this industry is central to what it does, not merely adjacent to it). Companies in the set: Achieve Life Sciences, Inc. (ACHV), Akebia Therapeutics, Inc. (AKBA), Alkermes plc (ALKS), ANI Pharmaceuticals, Inc. (ANIP), Ardelyx, Inc. (ARDX), Ascendis Pharma A/S (ASND), Aurinia Pharmaceuticals Inc. (AUPH), Journey Medical Corporation (DERM), Evolus, Inc. (EOLS), GSK plc (GSK), Heron Therapeutics, Inc. (HRTX), Indivior Pharmaceuticals Inc (INDV), Novartis AG (NVS), OPKO Health, Inc. (OPK), Pacira BioSciences, Inc. (PCRX), Phathom Pharmaceuticals, Inc. (PHAT), Regencell Bioscience Holdings Limited (RGC), Scilex Holding Company (SCLX), Sol-Gel Technologies Ltd. (SLGL), Takeda Pharmaceutical Company Limited (TAK), Theravance Biopharma Inc (TBPH), Trevi Therapeutics, Inc. (TRVI), Unicycive Therapeutics, Inc. (UNCY), Zoetis Inc. (ZTS), Zevra Therapeutics, Inc. (ZVRA). The market map groups them by business vertical — Pre-commercial branded therapeutic pipelines: 12 companies (ASND, AUPH, TRVI, ARDX, PHAT, TBPH, ZVRA, ACHV, HRTX, SLGL, AKBA, UNCY); Specialty brand and authorized-generic hybrid portfolios: 9 companies (TAK, ZTS, ALKS, INDV, RGC, ANIP, PCRX, EOLS, DERM); Diversified branded pharmaceutical platforms: 3 companies (NVS, GSK, SCLX); Adjacent: diagnostics-attached specialty pharma platforms: 1 company (OPK). 21 of the 25 companies carry a valid multiple on the primary valuation basis and form the rated set behind every cohort statistic; the others are shown but do not enter the statistics.
What was excluded and why
58 records failed a validation gate and never feed a statistic in this report (55 excluded from aggregate; 3 quarantined). Each exclusion, with its reason: ACHV — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ACHV — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ACHV — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ACHV — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · AKBA — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · AKBA — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · AKBA — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ALKS — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ARDX — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ARDX — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ARDX — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ASND — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · ASND — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · DERM — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · DERM — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · DERM — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · EOLS — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · EOLS — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · EOLS — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · EOLS — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · HRTX — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · HRTX — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · HRTX — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · HRTX — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · OPK — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · further items are listed in the companion tables.
Primary valuation basis and how it was chosen
Primary valuation basis: EV / Revenue on CY2027E consensus (21 of 25 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Practitioners price this industry on EV / Revenue rather than EV / EBITDA; validated coverage supports the industry standard (22 of 25 companies), so this report follows it. EV / Revenue on CY2027E is the lead convention: it is the sector-appropriate prior for Specialty and Branded Pharmaceuticals and it clears the coverage gate with 21 of 25 companies (84%). P / E is carried as a cross-check. A revenue lens is used rather than a profit multiple because the set is not consistently profitable on a forward basis (13 of 25 names with a meaningful EBITDA). The basis is selected in two steps: the industry's customary valuation conventions set the order of preference, and each convention is then tested for coverage — the share of companies with a valid, plausibility-checked multiple on the chosen period. A convention is used only when enough companies carry it; the best-covered convention is used, and disclosed, when none clears the threshold. Coverage measured for this report — EV / EBITDA: 13 of 25 companies; EV / rEVenue: 22 of 25 companies; P/E: 16 of 25 companies. 2 companies show a non-meaningful EV / EBITDA denominator and are excluded from that statistic. 6 companies show a non-meaningful P / E denominator and are excluded from that statistic.
How the multiples and statistics are computed
Enterprise value (EV) is market capitalisation at the as-of date plus total debt minus cash and equivalents from the latest reported balance sheet, reconciled against the platform's stored value and disclosed where the two differ. Forward multiples divide EV (or the share price for P/E) by the consensus estimate for the stated calendar period; trailing multiples use the last twelve months of reported figures from SEC filings. A multiple with a negative or immaterial denominator is treated as not meaningful and excluded from every statistic. Cohort statistics are medians and quartiles over the rated set only; a group median with fewer than three observations is shown as the single company's figure and labelled as such. Valuation tiers cut the rated set at its quartiles (tiers cut at the rated set's quartiles: Premium ≥4.0x, Core 1.3x–4.0x, Discount <1.3x — NeuraCap groupings). Revenue growth compares consecutive calendar-year consensus revenue; EBITDA margin divides consensus EBITDA by consensus revenue for the same period. Figures shown in this report and the calculation behind each: 2.7x = median(ev_revenue CY2027E) (21 rated companies) · 5.1x = median(ev_revenue CY2027E) within Premium tier (n=6) · 2.2x = median(ev_revenue CY2027E) within Core tier (n=11) · 1.0x = median(ev_revenue CY2027E) within Discount tier (n=4) · 2.1x = median(ev_revenue CY2027E) | growth ≥ 6% (n=10) · 2.8x = median(ev_revenue CY2027E) | growth < 6% (n=10) · 4.0x = median(ev_revenue CY2027E) | EBITDA margin ≥ 29% (n=7) · 1.6x = median(ev_revenue CY2027E) | EBITDA margin < 29% (n=6) · 39% = median Rule of 40 score (revenue growth + EBITDA margin) (n=13) · 4.8x = median(ev_revenue CY2027E) within balanced quadrant (n=3) · 3.7x = median(ev_revenue CY2027E) within marginOnly quadrant (n=4) · 1.6x = median(ev_revenue CY2027E) within growthOnly quadrant (n=4) · 2.3x = median(ev_revenue CY2027E) within neither quadrant (n=2) · 4.0x = ev_revenue CY2027E for ALKS (quadrant outlier)
Precedent transactions: what is in the record and why
The precedent record holds the M&A transactions in Specialty and Branded Pharmaceuticals recorded from SEC filings (8-K announcements and the documents they reference), newest first, with each value and multiple linked to the exact passage in the filing that states it. 125 transactions were recorded for this industry; 41 are shown. 84 recorded transactions with neither a disclosed value nor a multiple are omitted because they say nothing about price; they remain in the companion workbook. Deal multiples are enterprise value over the target's last-twelve-month revenue or EBITDA at announcement, as disclosed; they are not restated to the public basis and no spread to the public multiples is claimed. Before a transaction reaches the record it passes a screen for mirrored or duplicate filings of the same deal, for divestitures where the filer is the seller rather than the buyer, for carve-outs recorded under the parent's name, and for values whose citation describes something other than the price paid (a debt raise, a termination fee); such records are corrected or excluded and the correction is noted. Data-quality notes on this record: 56 × no evidence record; 76 × deal value unit unresolved; 14 × duplicate precedent id; 1 × self transaction; 4 × divestiture roles reassigned. Case studies lead with the 3 richest stories — disclosed value, a readable multiple, newest first.
Sources
Company financials and transaction terms come from the companies' own SEC filings on EDGAR (10-K, 10-Q and 8-K documents), linked from each figure in the report. Forward figures are analyst consensus estimates for the calendar periods shown. Share prices and market capitalisations are market data as of September 28, 2026. Treasury yields are published by the U.S. Department of the Treasury. 832 source documents stand behind this report; by publisher domain: sec.gov, home.treasury.gov (1). Every figure on every page is traceable to one of these records; nothing in the report is derived from outside data.
Interpretation and important notice
Tier labels, situation maps, the agenda and the implications pages are NeuraCap analytical views drawn from the recorded evidence and are labelled as such. The report is informational: it is not investment advice, not a recommendation to buy or sell any security, not an opinion of value and not an offer of any kind. Readers should perform their own diligence before acting on anything described here.
Sources linked in the report
- AUPH (sec.gov)
- TRVI (sec.gov)
- ARDX (sec.gov)
- PHAT (sec.gov)
- TBPH (sec.gov)
- ZVRA (sec.gov)
- ACHV (sec.gov)
- HRTX (sec.gov)
- AKBA (sec.gov)
- UNCY (sec.gov)
- ZTS (sec.gov)
- ALKS (sec.gov)
- INDV (sec.gov)
- RGC (sec.gov)
- ANIP (sec.gov)
- PCRX (sec.gov)
- EOLS (sec.gov)
- DERM (sec.gov)
- OPK (sec.gov)
- $11.9B (sec.gov)
- $299M (sec.gov)
- 2.1x (sec.gov)
- $166M (sec.gov)
- $26M (sec.gov)
- $4.4B (sec.gov)
- $736M (sec.gov)
- n/a (sec.gov)
- n/a (sec.gov)
- $112M (sec.gov)
- $3.3B (sec.gov)
- n/a (sec.gov)
- n/a (sec.gov)
- 8.8x (sec.gov)
- n/a (sec.gov)
- n/a (sec.gov)
- 4.6x (sec.gov)
- n/a (sec.gov)
- n/a (sec.gov)
- n/a (sec.gov)
- 11.9x (sec.gov)
- n/a (sec.gov)
- sec.gov (827) (sec.gov)
- home.treasury.gov (1) (home.treasury.gov)
This report is published for information only. It is not a recommendation to buy or sell any security, an offer or solicitation, an appraisal or a fairness opinion, and no fiduciary relationship is created by reading it. Multiples that fail NeuraCap’s plausibility gates are excluded and never plotted. See the full methodology and the disclaimer.
More coverage in Health Care
- M&A Update · 29 September 2026Surgical and Orthopedic Devices M&A update, 14–28 September 2026
- Sector Outlook · 29 September 2026Surgical and Orthopedic Devices Sector Outlook — September 2026
- M&A Update · 29 September 2026Therapeutic and Monitoring Devices M&A update, 14–28 September 2026
- Sector Outlook · 29 September 2026Therapeutic and Monitoring Devices Sector Outlook — September 2026
Want this analysis for a company in Specialty and Branded Pharmaceuticals?
Company valuation reports run the same method against a single business — public or private.
